

Attorney Docket No.: 10082.200-US

#11/c  
PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Kjærulff et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: October 16, 2001

Examiner: To be assigned

For: Transgenic Plants

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Before examination, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please cancel claims 13, 14, 16-18, 20-22, 28-31 and 33-34 without prejudice or disclaimer.

**REMARKS**


This amendment is submitted to cancel claims in order to reduce the filing fee. There is no new matter added, and entry of the amendment is respectfully requested.

This application contains a Sequence Listing. Applicants enclose a computer-readable form of the Sequence Listing. The content of the paper copy of the Sequence Listing and of the computer readable form is the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: October 16, 2001



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

09981009-101601